CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
CSL Limited (ASX:CSL) shares sit around 5% below the 52-week high, and while I wouldn’t be buying at today’s price level I would be looking to hold. Here are two reasons why.
The healthcare industry benefits from an ageing population. I look at two ASX shares, ResMed Inc (ASX:RMD) and CSL Limited (ASX:CSL).
Founded in the 1890s Ansell Limited (ASX: ANN) is one of Australia’s oldest (and most successful) manufacturing companies.
The 52-week high price for Cochlear Limited (ASX: COH) shares is $221.44. Up almost 20% in the last three months, could Cochlear reach these highs again?
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.01% at lunch.
Healthcare giant CSL Limited (ASX:CSL) has outlined the effects of transitioning to its own distributor model in China.
The ASX 200 (INDEXASX: XJO)(^AXJO) is expected to open lower today, the USA’s S&P 500 Index (.INX) rose by 0.95% on Thursday.
The ASX 200 (INDEXASX:XJO)(^AXJO) could be due for a big correction this year as it reached a recent high.
CSL Limited (ASX:CSL) shares are a favourite blue-chip for many ASX investors but, with the share price near $200, are the shares overrated?
